- Home
- USGO vs LUCD Comparison
USGO vs LUCD Comparison
Compare USGO & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- LUCD
- Stock Information
- Founded
- USGO 2015
- LUCD 2018
- Country
- USGO United States
- LUCD United States
- Employees
- USGO N/A
- LUCD N/A
- Industry
- USGO Precious Metals
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- USGO Basic Materials
- LUCD Health Care
- Exchange
- USGO Nasdaq
- LUCD Nasdaq
- Market Cap
- USGO 117.3M
- LUCD 105.0M
- IPO Year
- USGO 2023
- LUCD 2021
- Fundamental
- Price
- USGO $8.10
- LUCD $1.10
- Analyst Decision
- USGO Strong Buy
- LUCD Strong Buy
- Analyst Count
- USGO 1
- LUCD 4
- Target Price
- USGO $26.50
- LUCD $3.94
- AVG Volume (30 Days)
- USGO 30.8K
- LUCD 720.7K
- Earning Date
- USGO 08-13-2025
- LUCD 08-13-2025
- Dividend Yield
- USGO N/A
- LUCD N/A
- EPS Growth
- USGO N/A
- LUCD N/A
- EPS
- USGO N/A
- LUCD N/A
- Revenue
- USGO N/A
- LUCD $4,360,000.00
- Revenue This Year
- USGO N/A
- LUCD $22.80
- Revenue Next Year
- USGO N/A
- LUCD $221.19
- P/E Ratio
- USGO N/A
- LUCD N/A
- Revenue Growth
- USGO N/A
- LUCD 14.74
- 52 Week Low
- USGO $5.00
- LUCD $0.73
- 52 Week High
- USGO $14.46
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- USGO 50.28
- LUCD 58.59
- Support Level
- USGO $7.59
- LUCD $0.98
- Resistance Level
- USGO $7.95
- LUCD $1.06
- Average True Range (ATR)
- USGO 0.32
- LUCD 0.06
- MACD
- USGO 0.05
- LUCD 0.02
- Stochastic Oscillator
- USGO 63.62
- LUCD 100.00
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.